IL-2 treatment of B16F10 melanoma cells stimulates metastatic colonization in the liver. 1997

M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
Department of Cell Biology and Morphological Sciences, School of Medicine, University of the Basque Country, Leioa, Vizcaya, Spain.

We had previously shown that murine B16F10 melanoma cells express the receptor for IL-2, transcribe the gene for IL-2 and respond to its factor by increasing their proliferation. In the present work we have investigated the effect of in vitro IL-2 treatment on the metastatic ability of B16F10 cells. In vivo experiments showed that the metastatic colonization of the liver was notably higher after intrasplenic inoculation of IL-2-treated cells. However, no change was observed when cells were intravenously inoculated. In vitro, cells became more resistant to NK lysis although the cytometric analysis of class 1 MHC molecules revealed a decrease in H-2Kb expression. In contrast IL-2 induced a two fold increment in the expression of la antigen. On the other hand slot-blot analysis showed that IL-2 gene expression could be upregulated, however no free IL-2 was released into the culture medium of B16F10 cells. We conclude that IL-2 increases the ability of B16F10 cells to metastase to the liver. The increase in the resistance to NK activity and in la antigen expression could be involved in the mechanisms underlying this effect.

UI MeSH Term Description Entries
D007376 Interleukin-2 A soluble substance elaborated by antigen- or mitogen-stimulated T-LYMPHOCYTES which induces DNA synthesis in naive lymphocytes. IL-2,Lymphocyte Mitogenic Factor,T-Cell Growth Factor,TCGF,IL2,Interleukin II,Interleukine 2,RU 49637,RU-49637,Ro-23-6019,Ro-236019,T-Cell Stimulating Factor,Thymocyte Stimulating Factor,Interleukin 2,Mitogenic Factor, Lymphocyte,RU49637,Ro 23 6019,Ro 236019,Ro236019,T Cell Growth Factor,T Cell Stimulating Factor
D007694 Killer Cells, Natural Bone marrow-derived lymphocytes that possess cytotoxic properties, classically directed against transformed and virus-infected cells. Unlike T CELLS; and B CELLS; NK CELLS are not antigen specific. The cytotoxicity of natural killer cells is determined by the collective signaling of an array of inhibitory and stimulatory CELL SURFACE RECEPTORS. A subset of T-LYMPHOCYTES referred to as NATURAL KILLER T CELLS shares some of the properties of this cell type. NK Cells,Natural Killer Cells,Cell, NK,Cell, Natural Killer,Cells, NK,Cells, Natural Killer,Killer Cell, Natural,NK Cell,Natural Killer Cell
D008114 Liver Neoplasms, Experimental Experimentally induced tumors of the LIVER. Hepatoma, Experimental,Hepatoma, Morris,Hepatoma, Novikoff,Experimental Hepatoma,Experimental Hepatomas,Experimental Liver Neoplasms,Hepatomas, Experimental,Neoplasms, Experimental Liver,Experimental Liver Neoplasm,Liver Neoplasm, Experimental,Morris Hepatoma,Novikoff Hepatoma
D008546 Melanoma, Experimental Experimentally induced tumor that produces MELANIN in animals to provide a model for studying human MELANOMA. B16 Melanoma,Melanoma, B16,Melanoma, Cloudman S91,Melanoma, Harding-Passey,Experimental Melanoma,Experimental Melanomas,Harding Passey Melanoma,Melanomas, Experimental,B16 Melanomas,Cloudman S91 Melanoma,Harding-Passey Melanoma,Melanoma, Harding Passey,Melanomas, B16,S91 Melanoma, Cloudman
D008810 Mice, Inbred C57BL One of the first INBRED MOUSE STRAINS to be sequenced. This strain is commonly used as genetic background for transgenic mouse models. Refractory to many tumors, this strain is also preferred model for studying role of genetic variations in development of diseases. Mice, C57BL,Mouse, C57BL,Mouse, Inbred C57BL,C57BL Mice,C57BL Mice, Inbred,C57BL Mouse,C57BL Mouse, Inbred,Inbred C57BL Mice,Inbred C57BL Mouse
D006649 Histocompatibility Antigens A group of antigens that includes both the major and minor histocompatibility antigens. The former are genetically determined by the major histocompatibility complex. They determine tissue type for transplantation and cause allograft rejections. The latter are systems of allelic alloantigens that can cause weak transplant rejection. Transplantation Antigens,Antigens, Transplantation,Histocompatibility Antigen,LD Antigens,SD Antigens,Antigen, Histocompatibility,Antigens, Histocompatibility,Antigens, LD,Antigens, SD
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D012333 RNA, Messenger RNA sequences that serve as templates for protein synthesis. Bacterial mRNAs are generally primary transcripts in that they do not require post-transcriptional processing. Eukaryotic mRNA is synthesized in the nucleus and must be exported to the cytoplasm for translation. Most eukaryotic mRNAs have a sequence of polyadenylic acid at the 3' end, referred to as the poly(A) tail. The function of this tail is not known for certain, but it may play a role in the export of mature mRNA from the nucleus as well as in helping stabilize some mRNA molecules by retarding their degradation in the cytoplasm. Messenger RNA,Messenger RNA, Polyadenylated,Poly(A) Tail,Poly(A)+ RNA,Poly(A)+ mRNA,RNA, Messenger, Polyadenylated,RNA, Polyadenylated,mRNA,mRNA, Non-Polyadenylated,mRNA, Polyadenylated,Non-Polyadenylated mRNA,Poly(A) RNA,Polyadenylated mRNA,Non Polyadenylated mRNA,Polyadenylated Messenger RNA,Polyadenylated RNA,RNA, Polyadenylated Messenger,mRNA, Non Polyadenylated
D051379 Mice The common name for the genus Mus. Mice, House,Mus,Mus musculus,Mice, Laboratory,Mouse,Mouse, House,Mouse, Laboratory,Mouse, Swiss,Mus domesticus,Mus musculus domesticus,Swiss Mice,House Mice,House Mouse,Laboratory Mice,Laboratory Mouse,Mice, Swiss,Swiss Mouse,domesticus, Mus musculus

Related Publications

M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
January 1988, Clinical & experimental metastasis,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
April 2014, Anticancer research,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
January 1988, Experimental cell biology,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
January 2015, Molecular medicine reports,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
February 2022, Molecules (Basel, Switzerland),
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
August 2005, Journal of agricultural and food chemistry,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
October 2022, Antioxidants (Basel, Switzerland),
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
January 1998, Advances in experimental medicine and biology,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
August 2020, Biochemical pharmacology,
M D Boyano, and A Garcia de Galdeano, and I Smith-Zubiaga, and M L Cañavate
September 2015, Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society,
Copied contents to your clipboard!